Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 270-277

  Tasneen, Rokeya ^a   Betoudji, Fabrice ^a   Tyagi, Sandeep ^a   Li, Si Yang ^a   Williams, Kathy ^a   Converse, Paul J ^a   Dartois, Véronique ^b   Yang, Tian ^c   Mendel, Carl M ^c   Mdluli, Khisimuzi E ^c   Nuermberger, Eric L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; POSIZOLID; PRETOMANID; PYRAZINAMIDE; SUTEZOLID; TEDIZOLID; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; DRUG COMBINATION; NITROIMIDAZOLE DERIVATIVE; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; PNU-100480; QUINOLINE DERIVATIVE; RWJ-416457; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUBERCULOSIS; ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TIME FACTOR; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; DIARYLQUINOLINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; FEMALE; LINEZOLID; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; PYRAZINAMIDE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84957877941     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01691-15     Document Type: Article

References (35)

1. World Health Organization. 2014. Multidrug-resistant tuberculosis (MDR-TB) 2014 update. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/challenges/mdr/mdr-tb-factsheet.pdf?ua=1.
2. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. 2014. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18:1180-1187. http://dx.doi.org/10.5588/ijtld.14.0100.
3. Nuermberger E, Yew WW. 2015. Expanding the evidence base supporting shorter treatment durations for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 19:497-498. http://dx.doi.org/10.5588/ijtld.15.0110.
4. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684-692. http://dx.doi.org/10.1164/rccm.201001-0077OC.
5. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9:e102135. http://dx.doi.org/10.1371/journal.pone.0102135.
6. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979-2981. http://dx.doi.org/10.1128/AAC.00037-14.
7. Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL. 2015. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother 59:129-135. http://dx.doi.org/10.1128/AAC.03822-14.
8. Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH. 2014. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 9:e94462. http://dx.doi.org/10.1371/journal.pone.0094462.
9. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-3120. http://dx.doi.org/10.1128/AAC.00384-12.
10. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 180:371-376. http://dx.doi.org/10.1164/rccm.200904-0611OC.
11. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
12. Vera-Cabrera L, Gonzalez E, Rendon A, Ocampo-Candiani J, Welsh O, Velazquez-Moreno VM, Choi SH, Molina-Torres C. 2006. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother 50:3170-3172. http://dx.doi.org/10.1128/AAC.00571-06.
13. Hilliard JJ, Fernandez J, Melton J, Macielag MJ, Goldschmidt R, Bush K, Abbanat D. 2009. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob Agents Chemother 53:2028-2033. http://dx.doi.org/10.1128/AAC.00833-08.
14. Tasneen R, Li S-Y, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.
15. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49:2289-2293. http://dx.doi.org/10.1128/AAC.49.6.2289-2293.2005.
16. Balasubramanian V, Solapure S, Shandil R, Gaonkar S, Mahesh KN, Reddy J, Deshpande A, Bharath S, Kumar N, Wright L, Melnick D, Butler SL. 2014. Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis. Antimicrob Agents Chemother 58:4185-4190. http://dx.doi.org/10.1128/AAC.00137-14.
17. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-1524. http://dx.doi.org/10.1128/AAC.00074-08.
18. Drusano GL, Liu W, Kulawy R, Louie A. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 55:5300-5305. http://dx.doi.org/10.1128/AAC.00502-11.
19. Rouan M-C, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. 2012. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56:1444-1451. http://dx.doi.org/10.1128/AAC.00720-11.
20. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53:1314-1319. http://dx.doi.org/10.1128/AAC.01182-08.
21. Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, van Soolingen D, Kosterink JG, Uges DR, van der Werf TS. 2010. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 49:559-565. http://dx.doi.org/10.2165/11532080-000000000-00000.
22. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin CA. 2009. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 53:3981-3984. http://dx.doi.org/10.1128/AAC.01378-08.
23. Keel RA, Crandon JL, Nicolau DP. 2012. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother 56:3420-3422. http://dx.doi.org/10.1128/AAC.06121-11.
24. Keel RA, Tessier PR, Crandon JL, Nicolau DP. 2012. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother 56:4403-4407. http://dx.doi.org/10.1128/AAC.00122-12.
25. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 55:3453-3460. http://dx.doi.org/10.1128/AAC.01565-10.
26. Reele S, Xiao AJ, Das S, Balasubramanian V, Melnick D. 2011. A 14-day multiple ascending dose study: AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB), abstr A1-1735. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
27. Wallis RS, Diacon AH, Dawson R, Venter A, Friedrich SO, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Kadyszewski E. 2012. Safety, tolerability and early bactericidal activity in sputum of PNU-100480 (sutezolid) in patients with pulmonary tuberculosis, abstr THLBB02. Abstr XIX International AIDS Conference, Washington, DC.
28. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. 2012. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 40:1430-1442. http://dx.doi.org/10.1183/09031936.00022912.
29. Chang KC, Yew WW, Tam CM, Leung CC. 2013. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 57:4097-4104. http://dx.doi.org/10.1128/AAC.00120-13.
30. Flanagan S, McKee EE, Das D, Tulkens PM, Hosako H, Fiedler-Kelly J, Passarell J, Radovsky A, Prokocimer P. 2015. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother 59:178-185. http://dx.doi.org/10.1128/AAC.03684-14.
31. Schlosser MJ, Hosako H, Radovsky A, Butt MT, Draganov D, Vija J, Oleson F. 2015. Lack of neuropathological changes in rats administered tedizolid phosphate for nine months. Antimicrob Agents Chemother 59:475-481. http://dx.doi.org/10.1128/AAC.03950-14.
32. Converse PJ, Lee J, Williams KN, Tasneen R, Dionne K, Parish N, Wallis RS, Nuermberger E. 2012. Activity of PNU-100480 and its major metabolite in whole blood and broth culture models of tuberculosis, abstr 1563. Abstr 112th American Society for Microbiology General Meeting. American Society for Microbiology, Washington, DC.
33. Zhu T, Friedrich SO, Diacon A, Wallis RS. 2014. Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 58:3306-3311. http://dx.doi.org/10.1128/AAC.01920-13.
34. Lanoix JP, Lenaerts AJ, Nuermberger EL. 2015. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech 8:603-610. http://dx.doi.org/10.1242/dmm.019513.
35. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. 2012. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother 56:2342-2346. http://dx.doi.org/10.1128/AAC.06427-11.